Urinary N-Acetyl-β-d-Glucosaminidase (NAG) Levels and Risk of Cardiovascular Events in Diabetic Patients

作者：Weiwei Lou, Qun Cheng, Yanqiu Liang, Ding Xia · 发表于：International Journal of General Medicine · 年份：2021 · DOI：10.2147/ijgm.s337874 · 被引用次数：5 · 研究领域：Chronic Kidney Disease and Diabetes、Proteoglycans and glycosaminoglycans research、Advanced Glycation End Products research

Background: Cardiovascular diseases (CVDs) have a high incidence rate in population with diabetic patients. Studies on the association between urinary N-acetyl-β-d-glucosaminidase (NAG) levels, the biomarker of renal tubular damage, with cardiovascular (CV) events diabetic patients was still few. Methods: The relationship between urinary NAG levels and CV events was analyzed in a prospective cohort including 357 patients with type 2 diabetes mellitus at a follow-up of 5 years. Results: Twenty-six (7.3%) patients have CV events. Kaplan–Meier analysis suggested that diabetic patients with urine NAG levels ≥ 37.5 IU/L had a higher rate of CV events than those with urine NAG levels < 37.5 IU/L (Log rank test, P = 0.021). Cox analysis revealed that elevated urine NAG levels significantly contributed to increased risk of CV events (HR = 1.43, 95% CI 1.23– 1.93, P < 0.001) after adjusting for clinical confounding factors. Interestingly, we also found that “abnormal renal function” has an effect modification on the association between urine NAG levels and CV events. ROC-AUC analysis suggested that the urine NAG (AUC = 0.81, P < 0.001) had a better predictive value than eGFR (AUC = 0.74, P = 0.012). Conclusion: Elevated urine NAG levels are associated with higher risk of CV events in patients with type 2 diabetes. These results might further suggested that urinary NAG is a value urinary biomarker for early detecting CV events among diabetic patients. Keywords: N-acetyl-β-d-glucosamini...